Patents Assigned to Mirati Therapeutics, Inc.
  • LSD1 inhibitors
    Patent number: 9809541
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: November 7, 2017
    Assignee: Mirati Therapeutics, Inc.
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, Jr.
  • LSD1 Inhibitors
    Publication number: 20170183308
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: November 3, 2016
    Publication date: June 29, 2017
    Applicant: Mirati Therapeutics, Inc.
    Inventors: Matthew Arnold Marx, Arkadii Vaisburg, James Gail Christensen, Robert Anthony Galemmo, JR.
  • LSD1 Inhibitors
    Publication number: 20170129857
    Abstract: The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.
    Type: Application
    Filed: November 3, 2016
    Publication date: May 11, 2017
    Applicant: Mirati Therapeutics, Inc.
    Inventors: Arkadii Vaisburg, Matthew Arnold Marx